United Therapeutics (NASDAQ:UTHR) CEO Martine Rothblatt Sells 9,500 Shares

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine Rothblatt sold 9,500 shares of the business’s stock in a transaction on Thursday, July 2nd. The shares were sold at an average price of $554.61, for a total transaction of $5,268,795.00. Following the sale, the chief executive officer owned 40,513 shares in the company, valued at approximately $22,468,914.93. This trade represents a 19.00% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link.

United Therapeutics Price Performance

NASDAQ:UTHR opened at $555.91 on Friday. The firm’s 50-day moving average price is $558.71 and its 200-day moving average price is $527.64. The company has a market capitalization of $23.60 billion, a PE ratio of 20.52, a P/E/G ratio of 1.80 and a beta of 0.58. United Therapeutics Corporation has a 1-year low of $272.12 and a 1-year high of $609.35.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $7.00 by ($1.18). United Therapeutics had a net margin of 40.62% and a return on equity of 19.24%. The business had revenue of $781.50 million for the quarter, compared to analysts’ expectations of $797.40 million. During the same period last year, the business earned $6.63 earnings per share. The company’s revenue was down 1.6% on a year-over-year basis. Equities analysts anticipate that United Therapeutics Corporation will post 26.63 EPS for the current fiscal year.

Hedge Funds Weigh In On United Therapeutics

A number of hedge funds have recently added to or reduced their stakes in UTHR. Avoro Capital Advisors LLC increased its holdings in shares of United Therapeutics by 17.3% in the 4th quarter. Avoro Capital Advisors LLC now owns 2,606,060 shares of the biotechnology company’s stock worth $1,269,803,000 after purchasing an additional 383,838 shares in the last quarter. Wellington Management Group LLP lifted its holdings in shares of United Therapeutics by 74.5% during the fourth quarter. Wellington Management Group LLP now owns 2,441,492 shares of the biotechnology company’s stock valued at $1,189,617,000 after purchasing an additional 1,042,711 shares in the last quarter. AQR Capital Management LLC boosted its position in shares of United Therapeutics by 29.9% during the fourth quarter. AQR Capital Management LLC now owns 1,281,699 shares of the biotechnology company’s stock valued at $624,508,000 after buying an additional 295,221 shares during the last quarter. Janus Henderson Group PLC increased its holdings in United Therapeutics by 8.9% in the 1st quarter. Janus Henderson Group PLC now owns 866,930 shares of the biotechnology company’s stock worth $514,016,000 after buying an additional 70,829 shares in the last quarter. Finally, Darwin Global Management Ltd. purchased a new position in United Therapeutics in the 3rd quarter worth about $317,617,000. 94.08% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of analysts have recently commented on the company. Bank of America boosted their price target on United Therapeutics from $569.00 to $626.00 and gave the stock a “neutral” rating in a research report on Tuesday, March 31st. Royal Bank Of Canada reduced their price objective on United Therapeutics from $707.00 to $701.00 and set an “outperform” rating for the company in a research report on Thursday, May 7th. UBS Group lifted their price objective on United Therapeutics from $655.00 to $705.00 and gave the company a “buy” rating in a research note on Thursday, March 5th. Wells Fargo & Company raised United Therapeutics from an “equal weight” rating to an “overweight” rating and boosted their target price for the stock from $575.00 to $735.00 in a report on Thursday, May 7th. Finally, Weiss Ratings reissued a “buy (b)” rating on shares of United Therapeutics in a research note on Thursday, June 11th. Eleven research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. According to MarketBeat.com, United Therapeutics has a consensus rating of “Moderate Buy” and an average target price of $619.42.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.